Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258223 | 0.88 | MAPK14 (0.45) | MAPK14PTGS2PTGDR2ALOX5PTGS1 | |
| SCHEMBL14705610 | 0.81 | MAPK14 (0.39) | MAPK14PTGS2PTGDR2ALOX5PTGS1 | |
| SCHEMBL14705607 | 0.81 | PTGS2 (0.39) | MAPK14PTGS2PTGDR2ALOX5PTGS1 | |
| SCHEMBL3004677 | 0.77 | MAPK14 (0.44) | MAPK14PTGDR2ALOX5BCL2L1BAD | |
| SCHEMBL1778318 | 0.76 | HCRTR1 (0.45) | MAPK14PTGDR2ALOX5BCL2L1BAD | |
| SCHEMBL496233 | 0.76 | KDM4E (0.52) | MAPK14ALOX5BCL2L1BADALDH1A1 | |
| SCHEMBL270942 | 0.76 | HCRTR1 (0.51) | PTGS2ALOX5 | |
| SCHEMBL14706007 | 0.76 | MAPK14 (0.43) | MAPK14PTGDR2ALOX5BCL2L1BAD | |
| SCHEMBL14705600 | 0.75 | GRM2 (0.43) | ALOX5ALDH1A1 | |
| SCHEMBL27789562 | 0.74 | KDM4E (0.47) | PTGS2ALOX5ALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | MAPK14 113/4885PTGS2 3631/4885PTGDR2 1995/4885 |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | MAPK14 113/4885PTGS2 3631/4885PTGDR2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.